Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4101–4150 of 75328
On February 14, 2025, Jonathan Seeley joined the Company as its Vice President, FP&A and Treasury and was appointed Vice President, Treasurer in April 2025.
On April 16, 2025, the Company appointed Pamela M. Abowd as its Chief Accounting Officer.
appointed Bethany H. Corum as President of the Bank
elected Mrs. Corum as a member of the Board of Directors of the Bank
William G. Smith, Jr. notified CCBG of his resignation as President of CCBG and as Chairman of the Board of Capital City Bank, and Mr. Barron notified the Bank of resignation as President of the Bank, each effective as of July 1, 2025.
appointed Thomas A. Barron as the Chairman of the Board of Directors of the Bank, each effective as of July 1, 2025. 2. On May 28, 2025, the Board of Directors of CCBG appointed Mr. Barron as President of CCBG, effective as of July 1, 2025. In connection with these changes, on May 27, 2025, William G. Smith, Jr. notified CCBG of his resignation as President of CCBG and as Chairman of the Board of Capital City Bank, and Mr. Barron notified the Bank of resignation as President of the Bank, each effective as of July 1, 2025.
appointed Mr. Barron as President of CCBG, effective as of July 1, 2025.
On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.
On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.
One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.
Effective as of May 29, 2025, Kevin B. Reid, Sr. resigned as General Counsel and Corporate Secretary of the Company.
Sarah F. Colbert has been appointed to serve as General Counsel and Corporate Secretary of the Company, effective upon Mr. Reid’s resignation from such positions on May 29, 2025.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.
each of Fumihiro Kozato, Dr. Feng Kuo, Robert Cochran, Fun-Kai Liu, and Dr. Yaichi Aoshima ceased to serve on the board of directors
Michelle P. Ho's title was changed from Interim Chief Financial Officer to Chief Financial Officer
Fumihiro Kozato ceased to serve as the principal executive officer
Darron Ma ceased to serve as the principal operating officer
Chewei Lin became the sole director of the Surviving Corporation and was appointed as the President and Chairman of the Surviving Corporation
each of Fumihiro Kozato, Dr. Feng Kuo, Robert Cochran, Fun-Kai Liu, and Dr. Yaichi Aoshima ceased to serve on the board of directors
each of Fumihiro Kozato, Dr. Feng Kuo, Robert Cochran, Fun-Kai Liu, and Dr. Yaichi Aoshima ceased to serve on the board of directors
Dr. Feng Kuo was appointed as the Chief Executive Officer
On May 30, 2025, Anthony M. Corriggio provided notice to Cohen & Steers Income Opportunities REIT, Inc. (the “Company”) of his decision to retire from his positions as President and Chief Operating Officer of the Company, after a 33-year career in the real estate industry.
On June 2, 2025 Sutro Biopharma, Inc. (the “Company”) announced the appointment of Gregory K. Chow as its Chief Financial Officer, principal financial officer and principal accounting officer, effective as of June 2, 2025.
In connection with Ms. Alves’ appointment as the Company’s Senior Vice President, Chief Accounting Officer and principal accounting officer, the Company entered into an employment agreement with Ms. Alves on May 28, 2025 (the “ Employment Agreement ”).
Robert S. Chambers, previously serving as President, Americas, will assume the newly created executive role of President
M. Bryan Verbarendse, previously serving as Executive Vice President and Chief Operating Officer, Americas, will succeed Mr. Chambers as President, Americas.
John Rettig, the Company’s current President and Chief Financial Officer, will transition to serve as the Company’s President and Chief Operating Officer.
announcing the appointment of Rohini Jain as Chief Financial Officer of the Company, effective as of July 7, 2025
On May 29, 2025, the Company expanded the size of its Board of Directors (the “Board”) from seven members to eight members and, under the terms of the Merger Agreement, appointed Mr. John M. Engquist (who previously served as a member on the H&E board of directors) to the Board.
In connection with the consummation of the Acquisition, at the Effective Time on June 2, 2025, David Farren, Jennifer Laudermilch, and Derek Lively became directors of the Company.
Immediately prior to the Effective Time, each of the Executives resigned as officers of the Company, Brad Barber and John M. Engquist resigned from the board of directors of the Company
At the Effective Time, in accordance with the Merger Agreement, each of Paul N. Arnold, Gary W. Bagley, Bruce C. Bruckmann, Patrick L. Edsell, Thomas J. Galligan III, Lawrence C. Karlson, Jacob Thomas and Mary P. Thompson resigned from the board of directors of the Company.
In connection with the consummation of the Acquisition, at the Effective Time, Lawrence H. Silber as President, David Farren as Vice President, S. Wade Sheek as Secretary, Jennifer Laudermilch as Treasurer, Derek Lively as Assistant Secretary and Christian Cunningham as Chief Human Resource Officer became executive officers of the Company.
Immediately prior to the Effective Time, each of the Executives resigned as officers of the Company, Brad Barber and John M. Engquist resigned from the board of directors of the Company
At the Effective Time, in accordance with the Merger Agreement, each of Paul N. Arnold, Gary W. Bagley, Bruce C. Bruckmann, Patrick L. Edsell, Thomas J. Galligan III, Lawrence C. Karlson, Jacob Thomas and Mary P. Thompson resigned from the board of directors of the Company.
In connection with the consummation of the Acquisition, at the Effective Time on June 2, 2025, David Farren, Jennifer Laudermilch, and Derek Lively became directors of the Company.
Immediately prior to the Effective Time, each of the Executives resigned as officers of the Company, Brad Barber and John M. Engquist resigned from the board of directors of the Company
Immediately prior to the Effective Time, each of the Executives resigned as officers of the Company, Brad Barber and John M. Engquist resigned from the board of directors of the Company
In connection with the consummation of the Acquisition, at the Effective Time, Lawrence H. Silber as President, David Farren as Vice President, S. Wade Sheek as Secretary, Jennifer Laudermilch as Treasurer, Derek Lively as Assistant Secretary and Christian Cunningham as Chief Human Resource Officer became executive officers of the Company.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.